3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
57
Phase 1
29
Phase 3
11
Phase NA
8
Phase 1/2
8
Phase 4
3
Phase EARLY_PHASE1
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
3
Conditions
Breast Neoplasms
59
Neoplasms
24
Prostatic Neoplasms
21
Multiple Myeloma
18
Carcinoma, Non-Small-Cell Lung
15
Carcinoma, Hepatocellular
15
Stomach Neoplasms
11
Papillomavirus Infections
11
Lung Neoplasms
11
Colorectal Neoplasms
11
Melanoma
9
Neoplasm Metastasis
7
Leukemia, Myeloid, Acute
7
Waldenstrom Macroglobulinemia
6
Pain, Postoperative
6
Lymphoma, Non-Hodgkin
6
Leiomyoma
6
Hematologic Neoplasms
6
Brain Neoplasms
6
Thyroid Neoplasms
5
Smoking Cessation
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Polycystic Ovary Syndrome
5
Pain
5
Lymphoma
5
Glioma
5
Carcinoma, Renal Cell
5
Venous Thromboembolism
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Interventions
asciminib
2
nilotinib
1
bosutinib
1
Imatinib Mesylate
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 4
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
1 year
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT06427811
2026-04-17
ASC4INDIA
Novartis
Phase 4
Completed
85 enrolled
NCT07105319
2025-08-22
ROPEG
Eulji University Hospital
Phase 4
Completed
65 enrolled